Word

A2 BIO

Status

Pending

Status Code

688

Status Date

Tuesday, February 20, 2024

Serial Number

97796903

Mark Type

4000

Filing Date

Wednesday, February 15, 2023

Published for Opposition

Tuesday, December 26, 2023

Trademark Owner History

A2 Biotherapeutics, Inc. - Owner At Publication

Classifications

40 Custom manufacturing of therapeutics, biotherapeutics, medicines, and pharmaceuticals; manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells, in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cells, cellular targets, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease

5 Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes

42 medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeutics, biotherapeutics, medicines, pharmaceuticals; identification and development of, therapeutic targets for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for treatment and prevention of cancer, inflammation, and inflammatory diseases; research and development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information relating to treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services

A TWO BIO
"BIO"

Trademark Events

Feb 20, 2024

Noa E-Mailed - Sou Required From Applicant

Dec 26, 2023

Official Gazette Publication Confirmation E-Mailed

Dec 26, 2023

Published For Opposition

Dec 6, 2023

Notification Of Notice Of Publication E-Mailed

Nov 17, 2023

Approved For Pub - Principal Register

Nov 17, 2023

Examiner's Amendment Entered

Nov 17, 2023

Notification Of Examiners Amendment E-Mailed

Nov 17, 2023

Examiners Amendment E-Mailed

Nov 17, 2023

Examiners Amendment -Written

Nov 14, 2023

Assigned To Examiner

Mar 6, 2023

New Application Office Supplied Data Entered

Feb 18, 2023

New Application Entered